Journal of Peking University(Health Sciences) >
Progress in interferon: A treatment of Behcet syndrome
Received date: 2020-07-10
Online published: 2020-12-13
Behcet syndrome (BS) is a chronic systemic inflammatory disorder involving vessels of all sizes, characterized by relapsing episodes of oral and/or genital ulcers, as well as skin lesions. Ocular, vascular, gastrointestinal, neurological system involvement can cause significant morbidity and mortality. Glucocorticoids and immunosuppressants are the cornerstones for the management of BS. Biologic agents has been recommended for severe and/or refractory BS. Interferon-α (IFN-α) had multiple biological effects, such as antiviral and antiproliferative, that could regulate both innate and adaptive immunity in BS. Growing evidence showed the efficacy of IFN-α in severe and/or refractory BS. Many studies have demonstrated that IFN-α has comparable effectiveness and tolerance profiles as anti-tumor necrosis factor (TNF) agents for Behcet’s uveitis with a much lower cost and steroid-and immunosuppressant-sparing effects. IFN-α has been recommended as second-line therapy for ocular involvement of BS in EULAR (The European League Against Rheumatism) 2018. IFN-α also improves mucocutaneous lesions in BS with the dosage from 3 to 9-12 million IU three times per week. A few cases indicated the therapeutic potential of IFN-α in intestinal BS. As a new trial of IFN-α in vascular BS (VBS), a recent study revealed the lower relapse rate and higher recanalization rate with IFN-α in lower extremity deep vein thrombosis (DVT). Another two case reports presented the efficacy of IFN-α in pulmonary artery involvement in BS. Also, case reports have shown successful treatment in refractory neurological involvement. There are two subtypes of IFN-α commonly used in autoimmune diseases, named IFN-α2a and IFN-α2b. IFN-α2a seemed more effective than IFN-α2b, especially in ocular and mucocutaneous involvement of BS. Side effects of IFN-α are dose-dependent and not severe. The most frequent side effects are flu-like syndrome, mild leukopenia and alopecia. Considering the potential risk of tuberculosis (TB) and hepatitis B virus (HBV) reactivation of TNF-α inhibitors, IFN-α is safe due to its anti-HBV effect and protective effect on TB. In conclusion, IFN-α is a promising choice for severe and/or refractory BS patients, especially for those who are intolerant or contraindicant to other biological agents, such as TNF inhibitors. Further prospective controlled studies are warranted to confirm the efficacy and safety of IFN-α in BS.
Key words： Behcet syndrome; Biological agents; Interferon-α
Dong YAN , Wen-jie ZHENG . Progress in interferon: A treatment of Behcet syndrome[J]. Journal of Peking University(Health Sciences), 2020 , 52(6) : 1166 -1170 . DOI: 10.19723/j.issn.1671-167X.2020.06.032
| [1] | Ozguler Y, Leccese P, Christensen R, et al. Management of major organ involvement of Beh?et’s syndrome: a systematic review for update of the EULAR recommendations[J]. Rheumatology (Oxford), 2018,57(12):2200-2212. |
| [2] | 严冬, 赵岩, 曾小峰, 等. 生物制剂治疗重症和(或)难治性神经白塞病临床分析[J]. 中华风湿病学杂志, 2018,22(3):148-153. |
| [3] | Ding Y, Li C, Liu J, et al. Tocilizumab in the treatment of severe and/or refractory vasculo-Beh?et’s disease: a single-centre experience in China[J]. Rheumatology (Oxford), 2018,57(11):2057-2059. |
| [4] | Bare?i? M, Reihl M, Habek M, et al. Improvement of neurological and ocular symptoms of Beh?et’s disease after the introduction of infliximab[J]. Rheumatol Int, 2018,38(7):1301-1306. |
| [5] | Ayaz C, Celen MK, Colak H, et al. Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B[J]. Indian J Gastroenterol, 2006,25(2):71-73. |
| [6] | Aruna, Li L. anti-interferon alpha antibodies in patients with high-risk BCR/ABL-negative myeloproliferative neoplasms treated with recombinant human interferon-α[J]. Med Sci Monit, 2018,24:2302-2309. |
| [7] | Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions[J]. Annu Rev Biochem, 1987,56:727-777. |
| [8] | Tsambaos D, Eichelberg D, Goos M. Beh?et’s syndrome: treatment with recombinant leukocyte alpha-interferon[J]. Arch Dermatol Res, 1986,278(4):335-336. |
| [9] | Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh?et’s syndrome[J]. Ann Rheum Dis, 2018,77(6):808-818. |
| [10] | Theofilopoulos AN, Baccala R, Beutler B, et al. Type Ⅰ inter-ferons (alpha/beta) in immunity and autoimmunity[J]. Annu Rev Immunol, 2005,23:307-336. |
| [11] | Snell LM, McGaha TL, Brooks DG. Type Ⅰ interferon in chronic virus infection and cancer[J]. Trends Immunol, 2017,38(8):542-557. |
| [12] | Deniz R, Tulunay-Virlan A, Ture Ozdemir F, et al. Th17-inducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behcet’s disease[J]. Immunol Invest, 2017,46(5):518-525. |
| [13] | Ekinci NS, Alpsoy E, Karakas AA, et al. IL-17A has an important role in the acute attacks of Beh?et’s disease[J]. J Invest Dermatol, 2010,130(8):2136-2138. |
| [14] | Hamzaoui K, Hamzaoui A, Hentati F, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Beh?et’s disease[J]. J Rheumatol, 1994,21(12):2301-2306. |
| [15] | Albayrak O, Oray M, Can F, et al. Effect of Interferon alfa-2a treatment on adaptive and innate immune systems in patients with Beh?et disease uveitis[J]. Invest Ophthalmol Vis Sci, 2019,60(1):52-63. |
| [16] | Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease[J]. Rheumatology (Oxford), 2011,50(2):293-298. |
| [17] | Touzot M, Cacoub P, Bodaghi B, et al. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Beh?et disease[J]. Autoimmun Rev, 2015,14(5):370-375. |
| [18] | Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells[J]. Nat Rev Immunol, 2010,10(3):170-181. |
| [19] | Pirhonen J, Sirén J, Julkunen I, et al. IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages[J]. J Leukoc Biol, 2007,82(5):1185-1192. |
| [20] | Metzger R, Heckl-Ostreicher B, Nerl C, et al. Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia: leukemic gamma delta+ T cells are resistant to growth stimulation in vitro but respond to interferon-alpha treatment in vivo[J]. Leuk Res, 1992,16(11):1087-1095. |
| [21] | Eguchi K, Kawakami A, Nakashima M, et al. Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells[J]. Clin Exp Immunol, 1992,88(3):448-454. |
| [22] | Koie T, Suzuki K, Shimoyama T, et al. Effect of interferon-alpha on production of reactive oxygen species by human neutrophils[J]. Luminescence, 2001,16(1):39-43. |
| [23] | K?tter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Beh?et disease: review of the literature[J]. Semin Arthritis Rheum, 2004,33(5):320-335. |
| [24] | Luxon BA, Grace M, Brassard D, et al. Pegylated interferons for the treatment of chronic hepatitis C infection[J]. Clin Ther, 2002,24(9):1363-1383. |
| [25] | Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Beh?et disease: an analysis of 880 patients[J]. Am J Ophthalmol, 2004,138(3):373-380. |
| [26] | K?tter I, Eckstein AK, Stübiger N, et al. Treatment of ocular symptoms of Beh?et’s disease with interferon alpha 2a: a pilot study[J]. Br J Ophthalmol, 1998,82(5):488-494. |
| [27] | Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh?et uveitis[J]. Arch Ophthalmol, 2011,129(3):288-294. |
| [28] | Eser-Ozturk H, Sullu Y. The results of interferon-alpha treatment in Beh?et uveitis[J]. Ocul Immunol Inflamm, 2020,28(3):498-504. |
| [29] | Shi J, Zhao C, Zhou J, et al. Effectiveness and safety of inter-feron α2a as an add-on treatment for refractory Beh?et’s uveitis[J]. Ther Adv Chronic Dis, 2019,10:1-9. |
| [30] | Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Beh?et’s disease-related uveitis: a multicenter retrospective observational study[J]. Clin Rheumatol, 2017,36(1):183-189. |
| [31] | Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh?et’s disease: a multicenter study[J]. Ophthalmology, 2014,121(10):1877-1884. |
| [32] | Yal?indag N, K?se HC. Comparison of the treatment results for beh?et’s uveitis in patients treated with infliximab and interferon[J]. Ocul Immunol Inflamm, 2020,28(2):305-314. |
| [33] | Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Beh?et’s syndrome: a systematic review for update of the EULAR recommendations for the management of Beh?et’s syndrome[J]. Semin Arthritis Rheum, 2019,48(4):752-762. |
| [34] | K?tter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh?et disease: results of an open 4-center trial[J]. Semin Arthritis Rheum, 2004,33(5):311-319. |
| [35] | Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Beh?et disease: a randomized placebo-controlled and double-blind study[J]. Arch Dermatol, 2002,138(4):467-471. |
| [36] | Esatoglu SN, Hatemi G. Update on the treatment of Beh?et’s syndrome[J]. Intern Emerg Med, 2019,14(5):661-675. |
| [37] | Grimbacher B, Wenger B, Deibert P, et al. Loss of vision and diarrhoea[J]. Lancet, 1997,350(9094):1818. |
| [38] | Monastirli A, Chroni E, Georgiou S, et al. Interferon-α treatment for acute myelitis and intestinal involvement in severe Beh?et’s disease[J]. QJM, 2010,103(10):787-790. |
| [39] | Demir S, Sag E, Kaya Akca U, et al. The challenge of treating pulmonary vasculitis in Beh?et disease: two pediatric cases[J]. Pediatrics, 2019,144(2):162. |
| [40] | Ozguler Y, Hatemi G, Cetinkaya F, et al. Clinical course of acute deep vein thrombosis of the legs in Beh?et’s syndrome[J]. Rheumatology (Oxford), 2020,59(4):799-806. |
| [41] | Yan D, Liu J, Zhang Y, et al. The Clinical features and risk factors of parenchymal neuro-Behcet’s disease[J/OL]. J Immunol Res, 2019, 2019: 7371458[2020-07-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757281/. |
| [42] | Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of neuro-Beh?et’s disease: international consensus recommendations[J]. J Neurol, 2014,261(9):1662-1676. |
| [43] | Chroni E, Monastirli A, Polychronopoulos P, et al. Epileptic seizures as the sole manifestation of neuro-Beh?et’s disease: complete control under interferon-alpha treatment[J]. Seizure, 2008,17(8):744-747. |
| [44] | Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-alpha: a new therapeutic option in refractory juvenile Beh?et’s disease with CNS involvement[J]. Rheumatology (Oxford), 2008,47(7):1051-1053. |
| [45] | Nichols JC, Ince A, Akduman L, et al. Interferon-alpha 2a treatment of neuro-Behcet disease[J]. J Neuroophthalmol, 2001,21(2):109-111. |
| [46] | Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders[J]. Clin Immunol Immunopathol, 1992,65(1):70-74. |
| [47] | Keskin Y, Seyahi E, Poyraz C, et al. Interferon alfa-associated depression in patients with Beh?et’s syndrome: a prospective controlled study[J]. Clin Exp Rheumatol, 2014,32(4 Suppl 84):S175. |
| [48] | 王宇. 全国第五次结核病流行病学抽样调查资料汇编 [M]. 北京: 军事医学科学出版社, 2011: 17. |
| [49] | Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018,3(6):383-403. |
| [50] | Kisacik B, Pamuk ON, Onat AM, et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: report from a large multicenter cohort with high background prevalence[J]. J Rheumatol, 2016,43(3):524-529. |
| [51] | Chyuan IT, Hsu PN. Tumor necrosis factor: the key to hepatitis B viral clearance[J]. Cell Mol Immunol, 2018,15(8):731-733. |
| [52] | Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy[J]. J Am Acad Dermatol, 2009,60(6):1001-1017. |
| [53] | Lande R, Giacomini E, Grassi T, et al. IFN-alpha beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells[J]. J Immunol, 2003,170(3):1174-1182. |
/
| 〈 |
|
〉 |